tetano
Editor, Senior Moderator
BMC Infect Dis
. 2024 Apr 22;24(1):428.
doi: 10.1186/s12879-024-09311-2. Characteristics and outcomes of COVID-19 patients presumed to be treated with sotrovimab in NHS hospitals in England
Vishal Patel[SUP] 1 [/SUP], Bethany Levick[SUP] 2 [/SUP], Stephen Boult[SUP] 2 [/SUP], Daniel C Gibbons[SUP] 1 [/SUP], Myriam Drysdale[SUP] 3 [/SUP], Emily J Lloyd[SUP] 1 [/SUP], Moushmi Singh[SUP] 1 [/SUP], Helen J Birch[SUP] 1 [/SUP]
Affiliations
Background: The impact of the constantly evolving severe acute respiratory syndrome coronavirus 2 on the effectiveness of early coronavirus disease 2019 (COVID-19) treatments is unclear. Here, we report characteristics and acute clinical outcomes of patients with COVID-19 treated with a monoclonal antibody (mAb; presumed to be sotrovimab) across six distinct periods covering the emergence and predominance of Omicron subvariants (BA.1, BA.2, and BA.5) in England.
Methods: Retrospective cohort study using data from the Hospital Episode Statistics database from January 1-July 31, 2022. Included patients received a mAb delivered by a National Health Service (NHS) hospital as a day-case, for which the primary diagnosis was COVID-19. Patients were presumed to have received sotrovimab based on NHS data showing that 99.98% of COVID-19-mAb-treated individuals received sotrovimab during the study period. COVID-19-attributable hospitalizations were reported overall and across six distinct periods of Omicron subvariant prevalence. Subgroup analyses were conducted in patients with severe renal disease and active cancer.
Results: Among a total of 10,096 patients, 1.0% (n = 96) had a COVID-19-attributable hospitalization, 4.6% (n = 465) had a hospital visit due to any cause, and 0.3% (n = 27) died due to any cause during the acute period. COVID-19-attributable hospitalization rates were consistent among subgroups, and no significant differences were observed across periods of Omicron subvariant predominance.
Conclusions: Levels of COVID-19-attributable hospitalizations and deaths were low in mAb-treated patients and among subgroups. Similar hospitalization rates were observed whilst Omicron BA.1, BA.2, and BA.5 were predominant, despite reported reductions in in vitro neutralization activity of sotrovimab against BA.2 and BA.5.
Keywords: COVID-19; Monoclonal antibody; Omicron; Sotrovimab.
. 2024 Apr 22;24(1):428.
doi: 10.1186/s12879-024-09311-2. Characteristics and outcomes of COVID-19 patients presumed to be treated with sotrovimab in NHS hospitals in England
Vishal Patel[SUP] 1 [/SUP], Bethany Levick[SUP] 2 [/SUP], Stephen Boult[SUP] 2 [/SUP], Daniel C Gibbons[SUP] 1 [/SUP], Myriam Drysdale[SUP] 3 [/SUP], Emily J Lloyd[SUP] 1 [/SUP], Moushmi Singh[SUP] 1 [/SUP], Helen J Birch[SUP] 1 [/SUP]
Affiliations
- PMID: 38649824
- PMCID: PMC11036565
- DOI: 10.1186/s12879-024-09311-2
Background: The impact of the constantly evolving severe acute respiratory syndrome coronavirus 2 on the effectiveness of early coronavirus disease 2019 (COVID-19) treatments is unclear. Here, we report characteristics and acute clinical outcomes of patients with COVID-19 treated with a monoclonal antibody (mAb; presumed to be sotrovimab) across six distinct periods covering the emergence and predominance of Omicron subvariants (BA.1, BA.2, and BA.5) in England.
Methods: Retrospective cohort study using data from the Hospital Episode Statistics database from January 1-July 31, 2022. Included patients received a mAb delivered by a National Health Service (NHS) hospital as a day-case, for which the primary diagnosis was COVID-19. Patients were presumed to have received sotrovimab based on NHS data showing that 99.98% of COVID-19-mAb-treated individuals received sotrovimab during the study period. COVID-19-attributable hospitalizations were reported overall and across six distinct periods of Omicron subvariant prevalence. Subgroup analyses were conducted in patients with severe renal disease and active cancer.
Results: Among a total of 10,096 patients, 1.0% (n = 96) had a COVID-19-attributable hospitalization, 4.6% (n = 465) had a hospital visit due to any cause, and 0.3% (n = 27) died due to any cause during the acute period. COVID-19-attributable hospitalization rates were consistent among subgroups, and no significant differences were observed across periods of Omicron subvariant predominance.
Conclusions: Levels of COVID-19-attributable hospitalizations and deaths were low in mAb-treated patients and among subgroups. Similar hospitalization rates were observed whilst Omicron BA.1, BA.2, and BA.5 were predominant, despite reported reductions in in vitro neutralization activity of sotrovimab against BA.2 and BA.5.
Keywords: COVID-19; Monoclonal antibody; Omicron; Sotrovimab.